SCHEMBL15050237

SCHEMBL15050237

C[Si](C)(C)CCOCn1c(-c2ccccc2Cl)nc(Br)c1Br

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.37
GLA P06280 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
DGAT1 O75907 3/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
F11 P03951 1/20 0.33
CNR2 P34972 1/20 0.33
ATM Q13315 1/20 0.33
MYC P01106 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23781131 0.85 DGAT1 (0.39) KMT2ATDP1DGAT1ALDH1A1KDM4E
SCHEMBL67447 0.82 DGAT1 (0.40) DGAT1ALDH1A1KDM4EPOLBNPC1
SCHEMBL23781145 0.79 DGAT1 (0.38) HSD11B1KMT2ATDP1DGAT1ALDH1A1
SCHEMBL15050223 0.78 DGAT1 (0.47) HSD11B1GLAKMT2ATDP1DGAT1
SCHEMBL68112 0.76 DGAT1 (0.41) KMT2ATDP1DGAT1ALDH1A1KDM4E
SCHEMBL5213310 0.74 DGAT1 (0.37) DGAT1NPC1MYC
SCHEMBL66909 0.73 DGAT1 (0.47) DGAT1ALDH1A1KDM4ELMNAMYC
SCHEMBL15596098 0.73 DGAT1 (0.33) DGAT1NPC1
SCHEMBL67719 0.72 DGAT1 (0.35) DGAT1NPC1MYC
SCHEMBL17810234 0.72 DGAT1 (0.46) DGAT1NPC1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793894-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096642-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096642-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165472-A1 HETEROARYLS AND USES THEREOF PIK3R4, VPS4B, PIK3C2A HSD11B1 603/4885GLA 1399/4885KMT2A 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.